144 related articles for article (PubMed ID: 1337069)
1. Investigation of the in-vitro uptake, intraphagocytic biological activity and effects on neutrophil superoxide generation of dirithromycin compared with erythromycin.
Jooné GK; Van Rensburg CE; Anderson R
J Antimicrob Chemother; 1992 Oct; 30(4):509-23. PubMed ID: 1337069
[TBL] [Abstract][Full Text] [Related]
2. An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent.
Anderson R; Joone G; van Rensburg CE
J Antimicrob Chemother; 1988 Dec; 22(6):923-33. PubMed ID: 2977384
[TBL] [Abstract][Full Text] [Related]
3. Interactions of dirithromycin with human polymorphonuclear leukocytes.
Hand WL; Hand DL
Antimicrob Agents Chemother; 1993 Dec; 37(12):2557-62. PubMed ID: 8109917
[TBL] [Abstract][Full Text] [Related]
4. In vitro interaction between dirithromycin or its metabolite, erythromycylamine, and oxidative polymorphonuclear metabolism.
Moutard I; Gressier B; Brunet C; Dine T; Luyckx M; Cazin M; Cazin JC
J Antibiot (Tokyo); 1997 Jan; 50(1):53-7. PubMed ID: 9066766
[TBL] [Abstract][Full Text] [Related]
5. Time and concentration dependent influence of dirithromycin on neutrophils oxidative burst.
Levert H; Gressier B; Brunet C; Dine T; Luyckx M; Ballester L; Templier F; Cazin M; Cazin JC
J Antibiot (Tokyo); 1999 Feb; 52(2):127-33. PubMed ID: 10344566
[TBL] [Abstract][Full Text] [Related]
6. Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin/dalfopristin and erythromycin against Legionella species by intracellular susceptibility testing in HL-60 cells.
Stout JE; Arnold B; Yu VL
J Antimicrob Chemother; 1998 Feb; 41(2):289-91. PubMed ID: 9533475
[TBL] [Abstract][Full Text] [Related]
7. Effects of dirithromycin and erythromycylamine on human neutrophil degranulation.
Abdelghaffar H; Mtairag EM; Labro MT
Antimicrob Agents Chemother; 1994 Jul; 38(7):1548-54. PubMed ID: 7979287
[TBL] [Abstract][Full Text] [Related]
8. Modulation of human polymorphonuclear neutrophil function by macrolides: preliminary data concerning dirithromycin.
Labro MT; el Benna J; Abdelghaffar H
J Antimicrob Chemother; 1993 Mar; 31 Suppl C():51-64. PubMed ID: 8478312
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patients.
Rolston KV; Ho DH; LeBlanc B; Bodey GP
Eur J Clin Microbiol Infect Dis; 1990 Jan; 9(1):30-3. PubMed ID: 2137413
[TBL] [Abstract][Full Text] [Related]
10. Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and autooxidation.
Anderson R
J Infect Dis; 1989 May; 159(5):966-73. PubMed ID: 2540250
[TBL] [Abstract][Full Text] [Related]
11. Investigation of dirithromycin and erythromycylamine uptake by human neutrophils in vitro.
Mtairag EM; Abdelghaffar H; Labro MT
J Antimicrob Chemother; 1994 Mar; 33(3):523-36. PubMed ID: 8040116
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and antimicrobial evaluation of dirithromycin (AS-E 136; LY237216), a new macrolide antibiotic derived from erythromycin.
Counter FT; Ensminger PW; Preston DA; Wu CY; Greene JM; Felty-Duckworth AM; Paschal JW; Kirst HA
Antimicrob Agents Chemother; 1991 Jun; 35(6):1116-26. PubMed ID: 1929252
[TBL] [Abstract][Full Text] [Related]
13. In-vitro activity of dirithromycin against Chlamydia pneumoniae.
Roblin PM; Kutlin A; Sokolovskaya N; Hammerschlag MR
J Antimicrob Chemother; 1997 May; 39(5):647-9. PubMed ID: 9184366
[TBL] [Abstract][Full Text] [Related]
14. Dirithromycin disc susceptibility tests: interpretative criteria and quality control parameters.
Barry AL; Pfaller MA; Fuchs PC
J Antimicrob Chemother; 1993 Mar; 31 Suppl C():27-37. PubMed ID: 8478310
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of dirithromycin, a new macrolide antibiotic, against Mycoplasma species.
Rennie KA; Prasad ES; Wenman WM
Diagn Microbiol Infect Dis; 1994 Sep; 20(1):57-9. PubMed ID: 7867300
[TBL] [Abstract][Full Text] [Related]
16. Effect of azithromycin, roxithromycin and erythromycin on human polymorphonuclear leukocyte function against Staphylococcus aureus.
Pascual A; López-López G; Aragón J; Perea EJ
Chemotherapy; 1990; 36(6):422-7. PubMed ID: 1963394
[TBL] [Abstract][Full Text] [Related]
17. New drugs--reports of new drugs recently approved by the FDA. Dirithromycin.
Shinkai I; Ohta Y
Bioorg Med Chem; 1996 Apr; 4(4):521-2. PubMed ID: 8735838
[TBL] [Abstract][Full Text] [Related]
18. An in-vitro comparison of the intraphagocytic bioactivity of erythromycin and roxithromycin.
Anderson R; Van Rensburg CE; Jooné G; Lukey PT
J Antimicrob Chemother; 1987 Nov; 20 Suppl B():57-68. PubMed ID: 3429387
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results.
Biedenbach DJ; Jones RN; Lewis MT; Croco MA; Barrett MS
Diagn Microbiol Infect Dis; 1999 Apr; 33(4):275-82. PubMed ID: 10212755
[TBL] [Abstract][Full Text] [Related]
20. Influence of azithromycin and other macrolides on the intracellular killing of Staphylococcus aureus by human polymorphonuclear leucocytes of healthy donors and a patient with Chédiak-Higashi syndrome.
Paulsen P; Simon C; Peters O; Hedderich J; Heim P
Chemotherapy; 1992; 38(3):185-90. PubMed ID: 1324831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
